# The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

> **NCT01739933** · PHASE3 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 438 (actual)

## Conditions studied

- Sepsis
- Delirium
- Impaired Cognition

## Interventions

- **DRUG:** Dexmedetomidine
- **DRUG:** Propofol

## Key facts

- **NCT ID:** NCT01739933
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-15
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739933, "The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01739933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*